Targeting of RGD‐modified proteins to tumor vasculature: A pharmacokinetic and cellular distribution study
Astrid J. Schraa(University of Groningen), Grietje Molema(University Medical Center Groningen), Johannes H. Proost(University of Groningen), Dirk K. F. Meijer(University of Groningen), Henk E. Moorlag(University of Groningen), Erwin J. Bos(University of Groningen), Lou F. M. H. de Leij(University Medical Center Groningen), Robbert J. Kok(Utrecht University)
Cited by 73
Related Papers
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature
|Drug Resistance Updates|2005|461
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
|Advanced Drug Delivery Reviews|2013|396
Diverse origins of the myofibroblast—implications for kidney fibrosis
|Nature Reviews Nephrology|2015|305
Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: State-of-the-art and challenges
|International Journal of Pharmaceutics|2016|285